Parkinson’s disease psychosis management: an evidence based, experience informed, pragmatic approach

References

• Fenelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci. 2010;289:12–17. doi: 10.1016/j.ns.2009.08.014
   PubMed Web of Science ®Google Scholar
• Yunusa I, Rashid N, Seyedin R, et al. Comparative efficacy, safety and acceptability of pimavanserin and other atypical antipsychotics for Parkinson’s disease psychosis: systematic review and network meta-analysis. J Ger Psychiatry And Neurol. 2023;36(5):417–432. doi: 10.1177/08919887231154933
   PubMed Web of Science ®Google Scholar
• Layton JB, McQuay L, Forns J, et al. Risk of mortality associated with pimavanserin compared with atypical antipsychotics in patients with Parkinson’s disease-related psychosis. Presented at the 2022 American Society of Clinical Psychopharmacology (ASCP); 2022 May 31; Scottsdale, AZ.
   Google Scholar
• Layton JB, Forns J, McQuay LJ, et al. Mortality in patient with Parkinson’s disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study. Drug Saf. 2023;46(2):195-208. 2016–19. doi: 10.1007/s40264-022-01260-6
   Web of Science ®Google Scholar
• Layton JB, Forns J, Turner ME, et al. Falls and fractures in patients with Parkinson’s disease-related psychosis treated with Pimavanserin vs atypical antipsychotics: a cohort study. Drug-Real World Outcome. 2022;9(1):9–22. doi: 10.1007/s40801-021-00284-1
   PubMedGoogle Scholar
• Iketani R, Furushima D, Imai S, et al. Efficacy and safety of atypical antipsychotics for treatment of psychosis in Parkinson’s disease: a systematic review and Bayesian network meta-analysis. Park Rel Disord. 2020;78:82–90. doi: 10.1016/j.parkreldis.2020.07.021
   PubMed Web of Science ®Google Scholar
• Moshelder AD, Ma Y, Akhtar S, et al. Mortality among Parkinson’s disease patient treated with pimavanserin or atypical antipsychotics: an observational study of medicate beneficiaries. Am J Psychiatry. 2022;179(8):553–561. doi: 10.1176/appi.ajp.21090876
   PubMed Web of Science ®Google Scholar
• Hwang YJ, Alexander GC, An H, et al. Risk of hospitalization and death associated with pimavanserin use in older adults with Parkinson’s disease. Neurology. 2021;97(13):e1266–31275. doi: 10.1212/WNL.0000000000012601
   PubMed Web of Science ®Google Scholar
• Isaacson SH, Citrome L. Hallucinations and delusions in association with Parkinson’s disease psychosis: safety of current treatments and future directions. Exp Opin Drug Safety. doi: 10.1080/14740338.2022.2069240
   Google Scholar
• Nguyen TPP, Abraham DS, Thibault D, et al. Low continuation rate of antipsychotic therapy in Parkinson’s disease-intolerance, ineffectiveness or inertia? BMC neurol. 2021;21(1):240. doi: 10.1186/s12883-021-02265-x
   PubMed Web of Science ®Google Scholar
• Pagonabarraga J, Martinez-Hora S, Fernandez de Bobadilla R, et al. Minor hallucinations occur in drug naïve Parkinson’s disease patients even from the premotor phase. Mov Disord. 2016;31(1):345–352. doi: 10.1002/mds.26432
   Web of Science ®Google Scholar
• Pachi I, Papadopoulos V, Koros C, et al. Comprehensive evaluation of psychotic features and their clinical correlates in early Parkinson’s disease. J Parkinson Dis. 2023 Oct 9;13(7):1185–1197. doi: 10.3233/JPD-230056 Online ahead of print.
   Web of Science ®Google Scholar
• Szatmari S, Illigens BM, Siepmann T, et al. Neuropsychiatric symptoms in untreated Parkinson’s disease. Neuropsychiatr Dis Treat. 2017;13:815–26. doi: 10.2147/NDT.S130997
   PubMed Web of Science ®Google Scholar
• Aarsland D, Bronnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early, untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;30(8):928–930. doi: 10.1136/jnnp.2008.166959
   Google Scholar
• Friedman JH. Clozapine is severely underused in Parkinson disease patients. Mov Disord Clin Pract. 2022;9(8):1021–1024. doi: 10.1002/mdc3.13582
   PubMed Web of Science ®Google Scholar
• Pham Nguyen TP, Abraham DS, Thibault D, et al. Low continuation of antipsychotic therapy in Parkinson disease – intolerance, ineffectiveness, or inertia? BMC neurol. 2021;21(1):240. doi: 10.1186/s12883-021-02265-x
   PubMed Web of Science ®Google Scholar
• Chekani F, Holmes HM, Johnson ML, et al. Risk of mortality associated with atypical antipsychotic use: a national cohort study of older adults with depression and Parkinson’s disease. Am J Ger Psychiatry. 2020;28(10):1079–1088. doi: 10.1016/j.jagp.2020.01.193
   PubMed Web of Science ®Google Scholar
• Heim B, Peball M, Krismer F, et al. Pimavanserin: a truly effective treatment for Parkinson’s disease psychosis? A review of interventions. Neuropsychiatr Dis Treat. 2023 May 30;19:1303–1312.
   PubMed Web of Science ®Google Scholar
• Chou KL, Messing S, Oakes D, et al. Drug induced psychosis in Parkinson’s disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol. 2005;28(5):215–219. doi: 10.1097/01.wnf.0000180228.77802.32
   PubMed Web of Science ®Google Scholar
• Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22(8):1061–8. doi: 10.1002/mds.21382
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM IV TR. (WA), DC: American Psychiatric Association; 2000.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. DSM V. (WA), DC DSM V: American Psychiatric Association; 2013.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM V TR. (WA), DC DSM V TR: American Psychiatric Association; 2022.
   Google Scholar
• Goetz CG, Vogel C, Tanner CM, et al. Early dopaminergic drug-induced hallucinations in Parkinsonian patients. Neurology. 1993;51(3):811–814. doi: 10.1212/WNL.51.3.811
   Google Scholar
• Pachi I, Papadopoulos V, Koros C, et al. Comprehensive evaluation of psychotic features and their clinical correlates in early Parkinson’s disease. J Park Dis. 2023;13(7):1185–97. doi: 10.3233/JPD-230056
   Web of Science ®Google Scholar
• Lenka A, Pagonabarraga J, Pal PK, et al. Minor hallucinations in Parkinson’s disease: a subtle symptom with major clinical implications. Neurol. 2019;93(6):259–266. doi: 10.1212/WNL.0000000000007913
   PubMed Web of Science ®Google Scholar
• Bejr-Kasem H, Sampredo F, Marin-Lahoz J, et al. Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline. Eur J Neurol. 2021;28(2):438–447. doi: 10.1111/ene.14576
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340(10):757–63. doi: 10.1056/NEJM199903113401003
   PubMed Web of Science ®Google Scholar
• Pollack P, Tison F, Rascol O, et al. Clozapine in the drug induced psychosis in Parkinson’s disease: a randomized, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689–695. doi: 10.1136/jnnp.2003.029868
   PubMed Web of Science ®Google Scholar
• Trosch RM, Friedman JH, Lannon MC, et al. Clozapine in Parkinson’s disease psychosis: a retrospective analysis of a large multicentered clinical experience. Mov Disord. 1998;13(3):377–382. doi: 10.1002/mds.870130302
   PubMed Web of Science ®Google Scholar
• Friedman JH, Hershkowitz D. Clozapine use in a movement disorders clinic. Clin Neuropharmacol. 2022;45(4):95–98. doi: 10.1097/WNF.0000000000000510
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R. Pimavanserin for Parkinson’s disease psychosis: a randomized placebo controlled phase 3 trial. Lancet. 2014;383(9916):533–540
   PubMed Web of Science ®Google Scholar
• Akbar U, Friedman JH. Long term outcomes for psychosis in clinical practice. Clin Park Related Disord. 2022 Apr 13;6: 100143. doi: 10.1016/j.prdoa.2022.100143.
   PubMedGoogle Scholar
• Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin (2A) receptor inverse agonist for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacol. 2010;35(4):881–892. doi: 10.1038/npp.2009.176
   PubMed Web of Science ®Google Scholar
• Barbato L, Monge A, Stocchi F, et al. Melperone in the treatment of iatrogenic psychosis in Parkinson’s disease. Funct Neurol. 1996;11(4):201–207.
   PubMed Web of Science ®Google Scholar
• Friedman JH. Melperone is ineffective in treating Parkinson’s disease psychosis. Mov Disord. 2012;27(6):803–4. doi: 10.1002/mds.24942
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tintner R, Vuon KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;20(8):958. doi: 10.1002/mds.20474
   PubMed Web of Science ®Google Scholar
• Rabey JM, Prokhorov T, Miniovich A, et al. The effect of quetiapine in Parkinson’s disease (PD) psychotic patients: a double-blind labeled study of three months duration. Mov Disord. 2008;22(3):313. doi: 10.1002/mds.21116
   Web of Science ®Google Scholar
• Shotbolt P, Samuel M, Fox C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat. 2009;5:327–32. doi: 10.2147/NDT.S5335
   PubMed Web of Science ®Google Scholar
• Merims D, Balas M, Peretz C, et al. Rater blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol. 2006;29(6):331–337. doi: 10.1097/01.WNF.0000236769.31279.19
   PubMed Web of Science ®Google Scholar
• Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonism patient with dopaminergic psychosis. Clin Neuropharm. 2004;27(4):153–156. doi: 10.1097/01.wnf.0000136891.17006.ec
   PubMed Web of Science ®Google Scholar
• Kyle K, Bronstein JM. Treatment of psychosis in Parkinson’s disease and dementia with Lewy Bodies: a review. Park Rel Disord. 2020;75:55–62. doi: 10.1016/j.parkreldis.2020.05.026
   PubMed Web of Science ®Google Scholar
• Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy Bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012 Mar;14(3):CD006504.
   Google Scholar
• Seppi K, Ray Chaudhari K, Coelho M, et al. Update on treatments for nor-motor symptoms in Parkinson’s disease: an evidence based approach. Mov Disord. 2019;34(2):180–198. doi: 10.1002/mds.27602
   PubMed Web of Science ®Google Scholar
• Adamowicz M, Pflomm JM, Shah BM, et al. Medical letter. Med Lttr Drugs Ther. 2021 Feb 22;63(1618):25–32.
   PubMedGoogle Scholar
• Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord. 2006;21(11):1899–1907. doi: 10.1002/mds.21077
   PubMed Web of Science ®Google Scholar
• Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16(6):1171–1174. doi: 10.1002/mds.1204
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci. 2002;23(1):41–43. doi: 10.1007/s100720200022
   PubMed Web of Science ®Google Scholar
• Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol. 2002;25(2):107–110. doi: 10.1097/00002826-200203000-00009
   PubMed Web of Science ®Google Scholar
• Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin. 2002;18(5):258–264. doi: 10.1185/030079902125000813
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–2518. doi: 10.1056/NEJMoa041470
   PubMed Web of Science ®Google Scholar
• van Mierlo TJM, Foncke EMJ, Post B, et al. Rivastigmine for minor visual hallucinations in Parkinson’s disease. Brain Behav. 2021 Aug;11(8):e2257.
   PubMed Web of Science ®Google Scholar
• Riederer P, Lange KW, Kornhuber J, et al. Pharmacotoxic psychosis after memantine in Parkinson’s disease. Lancet. 1991;338(8773):1022–23. doi: 10.1016/0140-6736(91)91888-2
   PubMed Web of Science ®Google Scholar
• Tampi RR, Jeste DV. Dementia is more than memory loss. Neuropsychiatric symptoms of dementia and their non-psychiatric and psychiatric management. Am J Psychiatry. 2022;179(8):528–543. doi: 10.1176/appi.ajp.20220508
   PubMed Web of Science ®Google Scholar
• Friedman JH, Koller WC, Lannon MC, et al. Benztropine versus clozapine for the treatment of tremor in Parkinson’s disease. Neurology. 1997;48(4):1077–81. doi: 10.1212/WNL.48.4.1077
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Kennedy J, Dai J, et al. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson’s disease. A high potency effect of clozapine. Neuropsychopharmacol. 1995;12(1):39–45. doi: 10.1038/sj.npp.1380237
   PubMed Web of Science ®Google Scholar
• Lutz UC, Sirly A, Wiatr G, et al. Clozapine serum concentrations in dopamimetic psychosis in Parkinson’s disease and related disorders. Eur J Clin Pharmacol. 2014;70(12):1471–1476. doi: 10.1007/s00228-014-1772-0
   PubMed Web of Science ®Google Scholar
• Schatzberg AF, DeBattista C. Schatzberg’s manual of clinical psychopharmacology. Ninth ed. (WA), D.C: American Psychiatric Association Publishing; 2019.
   Google Scholar
• Clozapine package insert
   Google Scholar
• Cusick E, Gupta VP. Stat pearls (internet). Treasure Island (FL): StatPearls Publishing; 2023 Jan.
   Google Scholar
• Horn S, Richardson H, Xie SH, et al. Pimavanserin versus quetiapine for the treatment of Parkinson’s disease psychosis and dementia with Lewy bodies. Park Rel Disord. 2019;69:119–124. doi: 10.1016/j.parkreldis.2019.11.009
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Rashid N, Doshi D. Patients treated with pimavanserin or quetiapine for Parkinson’s disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries. J Med Econ. 2023;26(1):769–776. doi: 10.1080/13696998.2023.2220597
   PubMed Web of Science ®Google Scholar
• Prohorov T, Klein C, Miniovitz A, et al. The effect of quetiapine in Parkinson disease patients with and without dementia. An open label study using a structured interview. J Neurol. 2006;253(2):171. doi: 10.1007/s00415-005-0943-4
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Friedman JH, Jacques C. Rosenfeld M.Quetiapine for the treatment of drug induced psychosis in Parkinson’s disease. Mov Disord. 1999;14(3):484–487. doi: 10.1002/1531-8257(199905)14:3<484:AID-MDS1016>3.0.CO;2-B
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Okun MS, Rodriguez RI, et al. Quetiapine improves visual hallucinations in Parkinson’s disease but not through normalization of sleep architecture: results of a double blind polysomnography study. Int J Neurosci. 2009;119(12):2196. doi: 10.3109/00207450903222758
   PubMed Web of Science ®Google Scholar
• Friedman JH. Quetiapine for Parkinson’s disease psychosis: evidence-based medicine versus expert belief: a case study. Mov Disord. 2018;33(7):1186–7. doi: 10.1002/mds.27378
   PubMed Web of Science ®Google Scholar
• Moellentine C, Rummins T, Ahlskog JE, et al. Effectiveness of ECT in patients with parkinsonism. J Clin Neuropsychiatry Clin Neurosci. 1998;10(2):187–193. doi: 10.1176/jnp.10.2.187
   PubMed Web of Science ®Google Scholar
• Takamiya A, Seki M, Kudo S, et al. Electroconvulsive therapy for Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2021;36(1):50–58. doi: 10.1002/mds.28335
   PubMed Web of Science ®Google Scholar
• Friedman J, Gordon N. Electroconvulsive therapy in Parkinson’s disease. Convulsive Therapy. 1992;8(3):204–210.
   PubMedGoogle Scholar
• Friedman JH. Managing Parkinson’s disease in patients with schizophrenia. Park Rel Disord. 2011;17(3):198–200.
   PubMed Web of Science ®Google Scholar
• Rissardo JP, Durante I, Sharon I, et al. Pimavanserin and Parkinson’s disease psychosis: a narrative review. Brain Sci. 2022;12(10):1286. PMID:36291220; PCID:PMC9599742. doi: 10.3390/brainsci12101286.
   PubMed Web of Science ®Google Scholar